XML 81 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9
Selected Quarterly Financial Information (UNAUDITED) (Tables)
 12 Months Ended
Dec. 31, 2014
Selected Quarterly Financial Information (UNAUDITED) [Abstract]  
Selected Quarterly Financial Information
19. Selected Quarterly Financial Information (UNAUDITED)

Year Ended December 31, 2014
 
First
Quarter
  
Second
Quarter
  
Third
Quarter
  
Fourth
Quarter
Revenues, net
 
$
934,721
  
$
855,435
  
$
960,202
  
$
1,664,563
Operating expenses
  
12,072,564
   
13,917,109
   
13,097,791
   
16,804,318
Loss from operations
  
(11,137,843
)
 
  
(13,061,674
)
 
  
(12,137,589
)
 
  (15,139,755)
Net loss attributable to BioTime, Inc.(1)
  
(8,099,014
)
 
  
(9,520,190
)
 
  
(8,267,925
)
 
  
(11,086,716
)
                
Basic and diluted net loss per share
 $
(0.14
)
 
 $
(0.16
)
 
 $
(0.12
)
 
 $
(0.14
)
                
Year Ended December 31, 2013
               
Revenues, net
 
$
431,724
  
$
1,035,514
  
$
507,384
  
$
1,670,063
Acquired in-process research and development(2)
  
-
   
-
   
-
   
17,458,766
Operating expenses
  
8,811,633
   
9,151,965
   
10,709,337
   
13,504,740
Loss from operations
  
(8,379,909
)
 
  
(8,116,451
)
 
  
(10,201,953
)
 
  
(29,293,443
)
Net loss attributable to BioTime, Inc.(1)
  
(7,719,263
)
 
  
(7,549,765
)
 
  
(9,003,168
)
 
  
(19,612,314
)
                
Basic and diluted net loss per share
 $
(0.15
)
 
 $
(0.14
)
 
 $
(0.16
)
 
 $
(0.35
)

(1)Net of $7,375,611 and $3,280,695 of deferred income tax benefits for 2014 and 2013 respectively.
(2)Includes IPR&D expenses related to intangible assets acquired by Asterias from Geron under the Asset Contribution Agreement. IPR&D represents the value of incomplete research and development projects which Asterias intends to continue. See Notes 2 and 14.